# HD18 for Advanced Stages in Hodgkins Lymphoma

> **NCT00515554** · PHASE3 · COMPLETED · sponsor: **University of Cologne** · enrollment: 1500 (actual)

## Conditions studied

- Hodgkins Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** BEACOPP escalated

## Key facts

- **NCT ID:** NCT00515554
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2019-07
- **Final completion:** 2020-07
- **Target enrollment:** 1500 (ACTUAL)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515554, "HD18 for Advanced Stages in Hodgkins Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00515554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*